Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;331:713 (1 October), doi:10.1136/bmj.331.7519.713
Janice Hopkins Tanne
New York
| The first 150 words of the full text of this article appear below. |
After only two months as commissioner, but 30 years at the organisation, Lester Crawford, head of the Food and Drug Administration, abruptly resigned last Friday. He sent an email message to FDA staff members saying, "It is time, at the age of 67, to step aside."
President Bush immediately named Andrew von Eschenbach, director of the National Cancer Institute, as temporary commissioner. Dr von Eschenbach said he would continue to hold both jobs.
The New York Times this week reported an anonymous government official as claiming that Dr Crawford's resignation was related to the fact that he had not fully disclosed financial information during Senate hearings on his confirmation (Sep 24; Sect A: 1). Dr Crawford's wife, Catherine W Crawford, subsequently denied this on his behalf (New York Times, Sep 27; Sect A: 21).
Dr Crawford's resignation comes after a difficult year for the FDA, in which it
-->
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?